United States Biotechnology & Medical Research

Maravai LifeSciences Holdings Inc (MRVI)

Track

Track

Maravai LifeSciences Holdings Inc. has seen no insider trading activity within the last three months. The most recent transactions occurred in June 2026, involving planned and proposed sales by General Counsel Kurt Oreshack. Prior to this period, various executives and directors engaged in both buying and selling activities throughout late 2025.
Ticker: MRVI Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Maravai LifeSciences Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.2
ORESHACK KURT General Counsel Officer
Transaction date
Planned sale
Price
347.43
Quantity 70,567 -15.8%
Value US$4,921,792
3.2
ORESHACK KURT General Counsel Officer
Transaction date
Planned sale
Price
249.80
Quantity 15,066 +5.8%
Value US$4,868,390
3.2
ORESHACK KURT Officer Officer
Transaction date
Proposed sale
Price
196.15
Quantity 94,319
Value US$1,490,647
3.2
ORESHACK KURT General Counsel Officer
Transaction date
Planned sale
Price
5.06
Quantity 25,000 -6.5%
Value US$126,500
3.2
ORESHACK KURT Officer Officer
Transaction date
Proposed sale
Price
5.06
Quantity 25,000
Value US$126,500
3.2
PRAHALAD MURALI Former Director Non-Executive Director
Transaction date
Proposed sale
Price
3.33
Quantity 3,951
Value US$13,138
3.2
Hopfield Jessica Former Director Non-Executive Director
Transaction date
Proposed sale
Price
3.48
Quantity 53,951
Value US$187,526
2.4
LUCIER GREGORY T Non-Executive Director
Transaction date
Purchase
Price
3.67
Quantity 48,528 +45.5%
Value US$178,098
2.4
LUCIER GREGORY T Non-Executive Director
Transaction date
Purchase
Price
3.70
Quantity 51,472 +93.4%
Value US$190,446
2.4
Brust Bernd Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.25
Quantity 216,212 +86.3%
Value US$702,689
2.4
Brust Bernd Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.21
Quantity 93,358 +59.4%
Value US$299,679
2.4
Brust Bernd Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.24
Quantity 157,201 +inf%
Value US$509,331
3.2
ORESHACK KURT Officer Officer
Transaction date
Proposed sale
Price
5.03
Quantity 25,000
Value US$125,750
3.2
ORESHACK KURT General Counsel Officer
Transaction date
Planned sale
Price
5.03
Quantity 25,000 -13.0%
Value US$125,750
0.7
DeFord John A Non-Executive Director
Transaction date
Purchase
Price
5.75
Quantity 17,500 +33.3%
Value US$100,625
2.6
HULL CARL See Remarks Executive Director
Transaction date
Purchase
Price
5.64
Quantity 175,000 +inf%
Value US$987,000
2.9
GTCR INVESTMENT XI LLC Non-Executive Director Large shareholder
Transaction date
Sale
Price
9.82
Quantity 9,940,974 -33.0%
Value US$97,570,660
2.6
HULL CARL Chief Executive Officer Executive Director
Transaction date
Purchase
Price
26.94
Quantity 35,000 +inf%
Value US$942,900
3.2
SELLERS LISA See Remarks Officer
Transaction date
Purchase
Price
27.00
Quantity 18,888 +inf%
Value US$509,976
3.2
GRAY SUSANNAH Non-Executive Director
Transaction date
Purchase
Price
27.00
Quantity 20,000 +168.7%
Value US$540,000
3.2
PRAHALAD MURALI Non-Executive Director
Transaction date
Purchase
Price
27.00
Quantity 18,000 +151.9%
Value US$486,000
3.2
Hance Robert B Non-Executive Director
Transaction date
Purchase
Price
27.00
Quantity 10,000 +84.4%
Value US$270,000
3.2
Hopfield Jessica Non-Executive Director
Transaction date
Purchase
Price
27.00
Quantity 50,000 +421.9%
Value US$1,350,000
2.4
LUCIER GREGORY T Non-Executive Director
Transaction date
Purchase
Price
27.00
Quantity 15,000 +126.6%
Value US$405,000
3.2
ORESHACK KURT General Counsel Officer
Transaction date
Purchase
Price
27.00
Quantity 7,500 +inf%
Value US$202,500
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-10 2026-06-10 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
70,567 -15.8%
347.43
US$4,921,792 		70,567 -15.8% 347.43 US$4,921,792
2026-06-10 2026-06-10 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
15,066 +5.8%
249.80
US$4,868,390 		15,066 +5.8% 249.80 US$4,868,390
2026-06-10 2026-06-10 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
94,319
196.15
US$1,490,647 		94,319 196.15 US$1,490,647
2026-06-10 2026-06-09 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
25,000 -6.5%
5.06
US$126,500 		25,000 -6.5% 5.06 US$126,500
2026-06-09 2026-06-09 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
25,000
5.06
US$126,500 		25,000 5.06 US$126,500
2025-12-23 2025-12-23 PrS Proposed sale
3.2
PRAHALAD MURALI

Former Director

Non-Executive Director
3,951
3.33
US$13,138 		3,951 3.33 US$13,138
2025-12-19 2025-12-19 PrS Proposed sale
3.2
Hopfield Jessica

Former Director

Non-Executive Director
53,951
3.48
US$187,526 		53,951 3.48 US$187,526
2025-12-09 2025-12-08 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
48,528 +45.5%
3.67
US$178,098 		48,528 +45.5% 3.67 US$178,098
2025-12-09 2025-12-05 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
51,472 +93.4%
3.70
US$190,446 		51,472 +93.4% 3.70 US$190,446
2025-11-17 2025-11-13 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
216,212 +86.3%
3.25
US$702,689 		216,212 +86.3% 3.25 US$702,689
2025-11-13 2025-11-12 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
93,358 +59.4%
3.21
US$299,679 		93,358 +59.4% 3.21 US$299,679
2025-11-13 2025-11-11 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
157,201 +inf%
3.24
US$509,331 		157,201 +inf% 3.24 US$509,331
2025-01-31 2025-01-31 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
25,000
5.03
US$125,750 		25,000 5.03 US$125,750
2025-01-31 2025-01-31 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
25,000 -13.0%
5.03
US$125,750 		25,000 -13.0% 5.03 US$125,750
2024-11-14 2024-11-12 B Purchase
0.7
DeFord John A
Non-Executive Director
17,500 +33.3%
5.75
US$100,625 		17,500 +33.3% 5.75 US$100,625
2024-11-12 2024-11-11 B Purchase
2.6
HULL CARL

See Remarks

Executive Director
175,000 +inf%
5.64
US$987,000 		175,000 +inf% 5.64 US$987,000
2024-05-30 2024-05-28 S Sale
2.9
GTCR INVESTMENT XI LLC
Non-Executive Director Large shareholder
9,940,974 -33.0%
9.82
US$97,570,660 		9,940,974 -33.0% 9.82 US$97,570,660
2024-05-28 2024-05-28 PrS Proposed sale
Maravai Life Sciences Holdings 2, LLC

Owner
1,531,028
10.78
US$16,504,482 		1,531,028 10.78 US$16,504,482
2024-05-28 2024-05-28 PrS Proposed sale
Maravai Life Sciences Holdings, LLC

Owner
8,409,946
10.78
US$90,659,218 		8,409,946 10.78 US$90,659,218
2020-11-30 2020-11-25 B Purchase
2.6
HULL CARL

Chief Executive Officer

Executive Director
35,000 +inf%
26.94
US$942,900 		35,000 +inf% 26.94 US$942,900
2020-11-25 2020-11-24 B Purchase
3.2
SELLERS LISA

See Remarks

Officer
18,888 +inf%
27.00
US$509,976 		18,888 +inf% 27.00 US$509,976
2020-11-25 2020-11-24 B Purchase
3.2
GRAY SUSANNAH
Non-Executive Director
20,000 +168.7%
27.00
US$540,000 		20,000 +168.7% 27.00 US$540,000
2020-11-25 2020-11-24 B Purchase
3.2
PRAHALAD MURALI
Non-Executive Director
18,000 +151.9%
27.00
US$486,000 		18,000 +151.9% 27.00 US$486,000
2020-11-25 2020-11-24 B Purchase
3.2
Hance Robert B
Non-Executive Director
10,000 +84.4%
27.00
US$270,000 		10,000 +84.4% 27.00 US$270,000
2020-11-25 2020-11-24 B Purchase
3.2
Hopfield Jessica
Non-Executive Director
50,000 +421.9%
27.00
US$1,350,000 		50,000 +421.9% 27.00 US$1,350,000
2020-11-25 2020-11-24 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
15,000 +126.6%
27.00
US$405,000 		15,000 +126.6% 27.00 US$405,000
2020-11-25 2020-11-24 B Purchase
3.2
ORESHACK KURT

General Counsel

Officer
7,500 +inf%
27.00
US$202,500 		7,500 +inf% 27.00 US$202,500
Explore more

More insider trading research around Maravai LifeSciences Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America